Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$88.76 USD
-0.24 (-0.27%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $88.76 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.76 USD
-0.24 (-0.27%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $88.76 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review
by Zacks Equity Research
Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.
New Strong Sell Stocks for February 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Company News for Feb 6, 2020
by Zacks Equity Research
Companies In The News Are: COTY, CPRI, HUM, GILD.
Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates
by Sheraz Mian
In addition to featuring fresh research reports on Exxon (XOM), Chevron (CVX), IBM (IBM) and others, today's Research Daily provides the Q4 earnings season update.
Regeneron Expands Agreement to Develop Coronavirus Therapy
by Zacks Equity Research
Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod
by Zacks Equity Research
Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap
Disney, Gilead & Snap Post Mixed Quarters, Chipotle Beats
by Mark Vickery
Lots of fresh Q4 earnings results to sift through after Tuesday's closing bell, so we will dive right in.
Gilead Sciences (GILD) Misses Q4 Earnings Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -22.62% and 2.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Company News for Feb 4, 2020
by Zacks Equity Research
Companies in the news are: GILD, MAXR, INSM, ABG
Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.
Should You Buy Gilead (GILD) Ahead of Earnings?
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.
Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of the HIV franchise and the uptake of Yescarta along with pipeline updates, when Gilead (GILD) reports fourth-quarter 2019 results.
J&J (JNJ) Plans to Develop Vaccine for New Coronavirus
by Zacks Equity Research
J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.